AXLA

Axcella Health Inc.

0.93
USD
6.90%
0.93
USD
6.90%
0.70 3.03
52 weeks
52 weeks

Mkt Cap 35.51M

Shares Out 38.18M

Chat
Send me real-time posts from this site at my email

Axcella adds 20% as mid-stage trial indicates potential of NASH therapy

The ongoing global Phase 2b study EMMPACT is designed to evaluate daily AXA1125 medications at 22.6g or 33.9g doses against the placebo in 270 subjects with biopsy confirmed stage 2 or 3 NASH. The interim readout was based on findings from 82 patients at week 12 and 58 patients at week 24, about half of whom had type 2 diabetes mellitus. According to the company, the interim readout, conducted when the enrollment reached 30% of the target, demonstrated that those in the high dose arm at 24 weeks showed statistically significant improvements in the liver stiffness measurement (LSM) compared to placebo. In addition, both dose levels at 12 and 24 weeks for all subjects indicated statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation. The study drug was found to be very safe and well tolerated, consistent with previous data, AXLA added. The company expects to report topline 48-week biopsy data in 1H 2024. Read: Days ago, AXLA rival Akero Therapeutics (AKRO) rallied its peers after the company announced that its mid-stage trial for NASH candidate Efruxifermin reached the main goal.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue